MedTrace Logo

The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia

NCT01493622 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2011-12-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.

Conditions

Interventions

DRUG

minocycline

variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；

DRUG

placebo

variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；

Sponsors & Collaborators

  • Central South University

    lead OTHER

Principal Investigators

  • Zhao J Ping · The Second Xiangya Hospital, Central South University,China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-11-30
Completion
2011-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01493622 on ClinicalTrials.gov